Researchers have reported the first clinical trial of a cell therapy built from activated regulatory T cells, known as ATregs or Actileucel, which are derived from white blood cells of healthy blood donors. The treatment is designed to prevent graft-versus-host disease (GvHD), a potentially severe complication that can arise after allogeneic stem cell transplantation.
GvHD occurs when donor immune cells attack the recipient's body. By infusing activated regulatory T cells, the therapy aims to calm that immune response and lower the risk of tissue damage. The trial marks an early but notable step in testing whether donor-derived regulatory cells can be used safely in this setting.
According to the source, this is the first clinical trial for this particular approach. As with any initial study, further research will be needed to confirm how well it works and to establish its safety profile. No other sources were available for comparison, so the findings stand as a single report rather than a consensus.